vs
Side-by-side financial comparison of CMB.TECH NV (CMBT) and Hologic (HOLX). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $592.8M, roughly 1.8× CMB.TECH NV). CMB.TECH NV runs the higher net margin — 32.3% vs 17.1%, a 15.2% gap on every dollar of revenue. On growth, Hologic posted the faster year-over-year revenue change (2.5% vs -34.6%).
CMB.TECH, before October 2024 known as Euronav, is a crude oil tanker transport company, which consists of VLCCs, Suezmaxes and FSOs.
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
CMBT vs HOLX — Head-to-Head
Income Statement — Q4 FY2024 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $592.8M | $1.0B |
| Net Profit | $191.2M | $179.1M |
| Gross Margin | — | 56.0% |
| Operating Margin | 46.4% | 22.6% |
| Net Margin | 32.3% | 17.1% |
| Revenue YoY | -34.6% | 2.5% |
| Net Profit YoY | -63.3% | -10.9% |
| EPS (diluted) | $1.01 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | — | $1.0B | ||
| Q1 25 | — | $1.0B | ||
| Q4 24 | $592.8M | $1.0B | ||
| Q3 24 | — | $988.0M | ||
| Q2 24 | — | $1.0B | ||
| Q1 24 | — | $1.0B |
| Q4 25 | — | $179.1M | ||
| Q3 25 | — | $187.2M | ||
| Q2 25 | — | $194.9M | ||
| Q1 25 | — | $-17.4M | ||
| Q4 24 | $191.2M | $201.0M | ||
| Q3 24 | — | $178.6M | ||
| Q2 24 | — | $194.5M | ||
| Q1 24 | — | $169.9M |
| Q4 25 | — | 56.0% | ||
| Q3 25 | — | 55.6% | ||
| Q2 25 | — | 56.3% | ||
| Q1 25 | — | 37.5% | ||
| Q4 24 | — | 56.8% | ||
| Q3 24 | — | 56.4% | ||
| Q2 24 | — | 55.4% | ||
| Q1 24 | — | 53.3% |
| Q4 25 | — | 22.6% | ||
| Q3 25 | — | 22.6% | ||
| Q2 25 | — | 24.9% | ||
| Q1 25 | — | -0.7% | ||
| Q4 24 | 46.4% | 22.5% | ||
| Q3 24 | — | 23.3% | ||
| Q2 24 | — | 24.1% | ||
| Q1 24 | — | 20.7% |
| Q4 25 | — | 17.1% | ||
| Q3 25 | — | 17.8% | ||
| Q2 25 | — | 19.0% | ||
| Q1 25 | — | -1.7% | ||
| Q4 24 | 32.3% | 19.7% | ||
| Q3 24 | — | 18.1% | ||
| Q2 24 | — | 19.2% | ||
| Q1 24 | — | 16.7% |
| Q4 25 | — | $0.79 | ||
| Q3 25 | — | $0.84 | ||
| Q2 25 | — | $0.86 | ||
| Q1 25 | — | $-0.08 | ||
| Q4 24 | $1.01 | $0.87 | ||
| Q3 24 | — | $0.75 | ||
| Q2 24 | — | $0.82 | ||
| Q1 24 | — | $0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $38.9M | $2.4B |
| Total DebtLower is stronger | $2.6B | $2.5B |
| Stockholders' EquityBook value | $1.2B | $5.2B |
| Total Assets | $3.9B | $9.2B |
| Debt / EquityLower = less leverage | 2.20× | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.4B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | $38.9M | $2.0B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | — | $2.4B | ||
| Q1 24 | — | $2.2B |
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | $2.6B | $2.5B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.5B | ||
| Q1 24 | — | $2.6B |
| Q4 25 | — | $5.2B | ||
| Q3 25 | — | $5.0B | ||
| Q2 25 | — | $4.8B | ||
| Q1 25 | — | $4.6B | ||
| Q4 24 | $1.2B | $4.8B | ||
| Q3 24 | — | $5.1B | ||
| Q2 24 | — | $5.0B | ||
| Q1 24 | — | $4.8B |
| Q4 25 | — | $9.2B | ||
| Q3 25 | — | $9.0B | ||
| Q2 25 | — | $8.8B | ||
| Q1 25 | — | $8.5B | ||
| Q4 24 | $3.9B | $8.7B | ||
| Q3 24 | — | $9.2B | ||
| Q2 24 | — | $8.9B | ||
| Q1 24 | — | $8.7B |
| Q4 25 | — | 0.48× | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | 2.20× | 0.53× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 0.51× | ||
| Q1 24 | — | 0.53× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $204.4M | $229.9M |
| Free Cash FlowOCF − Capex | — | $215.2M |
| FCF MarginFCF / Revenue | — | 20.5% |
| Capex IntensityCapex / Revenue | — | 1.4% |
| Cash ConversionOCF / Net Profit | 1.07× | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $229.9M | ||
| Q3 25 | — | $355.1M | ||
| Q2 25 | — | $343.3M | ||
| Q1 25 | — | $169.4M | ||
| Q4 24 | $204.4M | $189.3M | ||
| Q3 24 | — | $367.0M | ||
| Q2 24 | — | $405.8M | ||
| Q1 24 | — | $292.4M |
| Q4 25 | — | $215.2M | ||
| Q3 25 | — | $341.4M | ||
| Q2 25 | — | $330.5M | ||
| Q1 25 | — | $153.9M | ||
| Q4 24 | — | $172.5M | ||
| Q3 24 | — | $350.6M | ||
| Q2 24 | — | $385.3M | ||
| Q1 24 | — | $279.6M |
| Q4 25 | — | 20.5% | ||
| Q3 25 | — | 32.5% | ||
| Q2 25 | — | 32.3% | ||
| Q1 25 | — | 15.3% | ||
| Q4 24 | — | 16.9% | ||
| Q3 24 | — | 35.5% | ||
| Q2 24 | — | 38.1% | ||
| Q1 24 | — | 27.5% |
| Q4 25 | — | 1.4% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 1.3% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | — | 1.7% | ||
| Q2 24 | — | 2.0% | ||
| Q1 24 | — | 1.3% |
| Q4 25 | — | 1.28× | ||
| Q3 25 | — | 1.90× | ||
| Q2 25 | — | 1.76× | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.07× | 0.94× | ||
| Q3 24 | — | 2.05× | ||
| Q2 24 | — | 2.09× | ||
| Q1 24 | — | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CMBT
Segment breakdown not available.
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
